Friday, June 12, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 137 of 1,261
  1. US 11903922

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  2. US 11905297

    OX2R compounds

    The Board of Regents of the University of Texas System · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  3. US 11904054

    Compositions and methods for delivering pharmaceutical agents

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  4. WO 2024033462

    CELLULES SOUCHES MÉSENCHYMATEUSES À UTILISER DANS LE TRAITEMENT DE L'HYPERSENSIBILITÉ AUX PIQÛRES D'INSECTES CHEZ DES ÉQUIDÉS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Feb 15, 2024 · Expires Feb 10, 2044

    granted
  5. US 11896672

    Targeted nucleic acid conjugate compositions

    ARBUTUS BIOPHARMA CORPORATION · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  6. US 11896658

    RSV vaccines and methods of production and use thereof

    The Board of Regents for Oklahoma State University · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  7. US 11896654

    DNA monoclonal antibodies targeting checkpoint molecules

    Inovio Pharmaceuticals, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  8. US 11897945

    Methods of treating allergy using anti-Bet v 1 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  9. US 11898165

    Engineered host cells and methods of use thereof

    MiNK Therapeutics, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  10. US 11896623

    Visco-supplement compositions, and methods of use thereof

    Prime Merger Sub, LLC · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  11. US 11896603

    Oligosaccharide as therapeutic agent for alcohol associated liver disease

    The Regents of the University of California · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  12. US 11896599

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  13. US 11896626

    Multistrain population control systems and methods

    The Regents of the University of California · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  14. US 11898166

    In vitro generation of thymic organoid from human pluripotent stem cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  15. US 11896007

    Pest control using natural pest control agent blends

    TYRATECH, INC. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  16. US 11898207

    Methods of isolating neoantigen-specific T cell receptor sequences

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  17. US 11896617

    Polynucleotides encoding rituximab-resistant chimeric antigen receptors

    Allogene Therapeutics, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  18. US 11896643

    Fibroblast binding agents and use thereof

    Orionis Biosciences, Inc · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  19. US 11897879

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  20. US 11897873

    Kappa opioid receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  21. US 11898158

    Methods and compositions for the treatment of lysosomal storage diseases

    Sangamo Therapeutics, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  22. US 11897932

    Receptors for ligand-dependent transcriptional regulation

    The Regents of the University of California · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  23. US 11896417

    Time-varying kinetic modeling of high temporal-resolution dynamic pet data for multiparametric imaging

    The Regents of the University of California · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  24. US 11896558

    Use of an RXR agonist and taxanes in treating Her2+ cancers

    The Board of Regents of the University of Texas System · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.